Investor Presentation First Nine Months of 2023

112 Investor presentation First nine months of 2023 Growth momentum has increased driven by demographics and utilisation of full product portfolio International Operations is diverse and covers 190 markets % 20 Historic sales growth in IO Value % 16% 30% Growth momentum in IO Novo NordiskⓇ 28% 20% 15% 8% >487m live with diabetes 16 12 >600m live with obesity 8 5% 4 IO's share of revenue FY 2022 الراس 10% 0 0% 2015 2022 Aug 2020 NAO 51% 49% ΙΟ Growth rate range NAO: North America Operations; IO: International Operations; Share of Growth not depicted due to high numbers; FY: Full Year Source (RHS): IQVIA Aug 2023, Value, MAT; Market values are based on the list prices NN Diabetes market share -Market growth NN Diabetes growth Aug 2023

View entire presentation